top of page

Kisunla (donanemab) - has been approved for use!

Updated: Jul 3

Following a FDA advisory committee meeting on June 10, 2024, where they committee voted to recommend approval of Eli Lilly's new Alzheimer's disease treatment drug Kisunla (donanemab), FDA issued an approval for its general use on July 2, 2024. Expectations are that this drug will help adults with intellectual disability living with dementia, and eventually apply also to adults with Down syndrome (after safety issues are addressed).

Recent Posts

See All

Dr. Bishop Speaks to NAPA Council

Dr. Kathleen Bishop, Vice President of the NTG, offered public comments on January 17, 2024 to the federal Advisory Council on Alzheimer's Research, Care, and Services. Her plea to the Council was int


bottom of page